Core Vct I Share Discussion Threads

[andrbea] 14/3/2018 16:05

pdz

Amaretto13 Mar '18 - 07:56 - 380 of 385


So JSW readily admit to looking seriously at Debiensko and now admit to wanting to look at Jan Karski and state they have plenty of cash to 'invest' in such mines.

Quite surprised at the subdued response so far given Praire only valued at approx £60 million whilst Debiensko recently valued at 400 million Euros.

[stamford hill] 14/3/2018 14:08

ffs not another one. He was ramping Carillion just before it went bust(the new CEO wouldn't take over a basket case wait for the bounce etc etc he said). Maybe he is just having a bad run..

[lucicavi] 14/3/2018 13:22

Bad timing with CR buying and pumpinng CVR which is suspended today

[cpap man] 14/3/2018 11:50

KRS



Again today KRS are blue

[cpap man] 14/3/2018 11:48

VLS



Moving up nicely now are VLS with a GAP to fill so shares should go as high as 40p

[cpap man] 14/3/2018 11:41

ARS



Wow....my ARS is on fire yet again!

[yawn3] 14/3/2018 09:57

GCM

Recent placing at 34p which was at 20% discount. Since then some very good news. Now just 27p look interesting play.

[the stigologist] 14/3/2018 08:13

PYC

This is going worldwide folks

Bio and Pharma companies will want this tech to go to the FDA with it

Nobody gets it yet but Physiomics is going to be a £100m+ maybe even £1000m+ company

Why do you think Dr Jim Millen ex of Glaxo Emerging Technology department decided to join a £0.5m tiddler ?

[the stigologist] 14/3/2018 08:13

PYC

This is going worldwide folks

Bio and Pharma companies will want this tech to go to the FDA with it

Nobody gets it yet but Physiomics is going to be a £100m+ maybe even £1000m+ company

Why do you think Dr Jim Millen ex of Glaxo Emerging Technology department decided to join a £0.5m tiddler ?

[cpap man] 14/3/2018 08:02

AST



RNS out from AST where there have been wide spread rumours of a massive fund raising and tons of shorting of AST

Well todays RNS confirms that THERE IS NO FUND RAISING

AST share price should start to recover now big time!

[the stigologist] 14/3/2018 08:00

PYC Physiomics leading the way in 'a new era of cancer care"

Incredible! No wonder they are endorsed/validated by UK Government / Oxford Uni / Oxford NHS / Merck etc

[the stigologist] 14/3/2018 08:00

PYC Physiomics leading the way in 'a new era of cancer care"

Incredible! No wonder they are endorsed/validated by UK Government / Oxford Uni / Oxford NHS / Merck etc

[cpap man] 14/3/2018 07:35

AST



RNS out from AST where there have been wide spread rumours of a massive fund raising and tons of shorting of AST

Well todays RNS confirms that THERE IS NO FUND RAISING

AST share price should start to recover now big time!

[the stigologist] 14/3/2018 07:25

PYC Physiomics

BOOOOOM !

Free money !

SUBSTANTIAL NON-DILUTIVE FUNDING

Partnering with UK Government and NHS and Oxford University

MASSIVE VALIDATION

Pharmas and Bios are going to be RUSHING to PARTNER with PYC to COMMERCIALISE this when it's ready... and they augment their core B2B offering as well

PYC has been totally transformed by Dr Jim Millen

The 1p to 32p move in November/December 2017 was simply the first recognition by the Market what was taking place

No wonder the ex-Founder reckons it is worth 100p+

[the stigologist] 14/3/2018 07:25

PYC Physiomics

BOOOOOM !

Free money !

SUBSTANTIAL NON-DILUTIVE FUNDING

Partnering with UK Government and NHS and Oxford University

MASSIVE VALIDATION

Pharmas and Bios are going to be RUSHING to PARTNER with PYC to COMMERCIALISE this when it's ready... and they augment their core B2B offering as well

PYC has been totally transformed by Dr Jim Millen

The 1p to 32p move in November/December 2017 was simply the first recognition by the Market what was taking place

No wonder the ex-Founder reckons it is worth 100p+

[plain sailing] 13/3/2018 15:52

This promising small-cap stock could be a millionaire maker in 2018
Paul Summers
26/12/2017



The suggestion that a single stock could lead some investors to become millionaires next year may sound fanciful but I think this is quite possible if events work out for small-cap drug discovery and development firm ImmuPharma (LSE: IMM). Let me explain.

Blockbuster potential

Over the last three months, shares in the AIM-listed company have climbed more than 200% in value as anticipation grows over the outcome of a Phase III clinical trial for Lupuzor — its 100%-owned potential treatment for Lupus.

Approximately five million people are believed to suffer from the chronic and potentially life-threatening autoimmune disease that can be a notoriously difficult to treat. In the last 50 years, only one therapy — GlaxoSmithKline‘s Benlysta — has been approved for use, despite its questionable efficacy and serious side-effects. In 2015, the drug achieved sales of over $400m. By 2020, this figure is expected to rise to $1bn.

Positively, data from Lupozor’s Phase IIb trial indicated that ImmuPharma’s treatment — which modulates rather than blocks the immune system — was both effective and safe. Moreover, the effectiveness of Lupuzor increased even after the three-month trial’s conclusion. Investors will be hoping that the 52-week, randomised and double-blinded study currently in progress (involving patients in the US, Europe and Mauritius) yields similar results.

In its most recent update on 21 December, the company revealed that all 200 participants had now received the full 12-month dosage and that the “robust safety record” shown in earlier trials continues to be seen. According to Chairman Tim McCarthy, the company looks forward “with continued confidence” to reporting on top-line results in Q1 of next year.

In the event of a positive outcome, ImmuPharma will then seek to exploit its Fast Track designation and push for approval from the Food and Drug Administration (FDA). Once received, the company would then be free to seek out a global licensing deal for taking Lupuzor to market or — perhaps more likely — consider takeover bids by deep-pocketed pharmaceutical giants at a price befitting its blockbuster potential. Given the suggestion that it could be used in the treatment of other diseases, the price could easily be in the billions of pounds. Right now, ImmuPharma’s market cap is a little over £200m.

Despite the encouraging outcomes of previous trials, the possibility of the drug failing to impress still remains. Plenty of highly promising treatments have disappointed at the last hurdle, resulting in significant capital losses for investors. Unless you’re willing to embrace this level of risk, Immupharma shouldn’t even make it on to your watchlist, let alone into your portfolio.

That’s why — as a holder of its stock — only a small proportion of my capital is invested in the company. This money can be lost. I might grumble and curse but — thanks to a degree of diversification — I won’t lose my shirt.

That said, if — and it remains a sizeable ‘if‘ — Lupuzor proves effective (or at least more efficacious than Benlysta), I’m confident that ImmuPharma could generate huge wealth for investors in a very short time period.

[yawn3] 13/3/2018 15:31

AMP

Tick Tick

[cpap man] 13/3/2018 07:22

ARCM looking rather cheap!

[sux_2bu] 12/3/2018 21:33

When's CR returning ?

[the stigologist] 12/3/2018 19:11

PYC Physiomics

Today on the same day PYC announced successful completion of their 'Personalised Medicine Cancer Decision Support Tool' project with Government/InnovateUK/Oxford University (and they had applied for next stage funding)

The Government/InnovateUK have announced £300m funding for 'Precision Medicine'

Anyone reckon PYC in line for some SIGNIFICANT NON-DILUTIVE FUNDING soon ?

[the stigologist] 12/3/2018 19:11

PYC Physiomics

Today on the same day PYC announced successful completion of their 'Personalised Medicine Cancer Decision Support Tool' project with Government/InnovateUK/Oxford University (and they had applied for next stage funding)

The Government/InnovateUK have announced £300m funding for 'Precision Medicine'

Anyone reckon PYC in line for some SIGNIFICANT NON-DILUTIVE FUNDING soon ?